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Abstract
Colon cancer constitutes the second most common cause of cancer death in many Western 
countries. The PTEN tumour suppressor gene, located on chromosome 10q23.3, is now 
recognised as the most highly mutated tumour suppressor gene. PTEN, a lipid and protein 
phosphatase, regulates the phosphatidylinositol 3-kinase (PI3K)/ Akt signalling pathway and 
modulates cell cycle progression and cell survival. Previous work at University of 
Technology of Sydney laboratory has shown that a significant proportion of sporadic 
colorectal tumours harbour PTEN mutations that alter gene function and may therefore 
contribute to the pathways of colorectal carcinogenesis. A total of 10 novel somatic mutations 
have been described. In order to determine the functional consequences of these colon 
cancer-associated PTEN mutations, the wild type (WT) PTEN gene was cloned into a 
mammalian expression vector system and each of the mutants were generated from this. The 
WT, and each of the mutant K62R, Y65C, K125E, K125X, E150Q, D153N, D153Y, V217A 
319X and N323K PTEN constructs were then transiently transfected into an U87MG 
glioblastoma PTEN null cell line and HCT116 colon cancer PTEN expressing cell lines that 
were then assayed for cell cycle phase distribution, Akt phosphorylation levels and cell 
proliferation. The analyses of endogenous suppression of Phospho Akt assay indicates 50% 
of PTEN mutants (Y65C, K125E, K125X, D153N, and 319 X) shows deficiency in the 
U87MG cell line and 70% of the mutants in the EICT116 cell line (Y65C, K125E, K125X, 
D153N, D153\ V217A and 319X) had deficiency in suppressing endogenous
phosphorylated Akt. The results obtained show 50% (Y65C, K125X, K125E, D153N and 
319X) of the PTEN mutants had functional deficiency in cell cycle inhibitory capacity in the 
S phase in the U87MG cells; in contrast 80% (Y65C, K125X, K125E, E150Q, D153N, 
D153Y, V217A and 319X) of the PTEN mutants had functional deficiency in cell cycle 
inhibitory capacity in the S phase in the HCT116 cells. The results obtained show 60% of the 
PTEN mutants (K62R, Y65C, K125E, K125X, D153N and 319X) had alteration in cell 
proliferation rate in U87MG cells. In contrast in the HCT116 cell lines, 80% of the PTEN 
mutants (Y65C, K125E, K125X, E150Q, D153N, D153Y, V217A and 319X) had alteration 
in cell proliferation rates. These three functional assays of the mutations tested show an 
alteration of PTEN function. This was observed as a marked reduction in the ability of these 
PTEN mutants to bring about a level of cycle arrest, reduction of Akt phosphorylation levels 
and cell proliferation, compared to that observed with the WT PTEN gene product. These 
studies reveal that PTEN gene somatic mutations do alter PTEN function and are therefore
xix
likely to contribute to the process of colorectal carcinogenesis and may mediate a PTEN- 
associated carcinogenic pathway in these tumours.
xx
